Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

CMV Management with Specific Immunoglobulins: A Multicentric Retrospective Analysis on 92 Allotransplanted Patients.

Malagola M, Greco R, Santarone S, Natale A, Iori AP, Quatrocchi L, Barbieri W, Bruzzese A, Leotta S, Carotti A, Pierini A, Bernardi S, Morello E, Polverelli N, Turra A, Cattina F, Gandolfi L, Rambaldi B, Lorentino F, Serio F, Milone G, Velardi A, Foà R, Ciceri F, Russo D, Peccatori J.

Mediterr J Hematol Infect Dis. 2019 Sep 1;11(1):e2019048. doi: 10.4084/MJHID.2019.048. eCollection 2019.

2.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).

Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, Parma M, Bruno B, Sora F, Bernasconi P, Saccardi R, Foà R, Sessa M, Bresciani P, Giglio F, Picardi A, Busca A, Sica S, Perruccio K, Zucchetti E, Diral E, Iori AP, Colombo AA, Tringali S, Santarone S, Irrera G, Mancini S, Zallio F, Malagola M, Albano F, Carella AM, Olivieri A, Tecchio C, Dominietto A, Vacca A, Sorasio R, Orciuolo E, Risitano AM, Leotta S, Cortelezzi A, Mammoliti S, Oldani E, Bonifazi F; GITMO.

Biol Blood Marrow Transplant. 2019 Aug 7. pii: S1083-8791(19)30509-9. doi: 10.1016/j.bbmt.2019.07.037. [Epub ahead of print]

PMID:
31400502
3.

Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?

Malagola M, Polverelli N, Cancelli V, Morello E, Turra A, Borlenghi E, Cattina F, Rambaldi B, Bernardi S, Zanaglio C, Dereli Eke E, Gandolfi L, Farina M, Russo D.

Case Rep Hematol. 2019 Jun 11;2019:3914828. doi: 10.1155/2019/3914828. eCollection 2019.

4.

Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome.

Cattaneo C, Gramegna D, Malagola M, Pagani C, Borlenghi E, Cerqui E, Passi A, Sciumé M, Bernardi S, Crippa C, Dalceggio D, Carbone C, Pelizzari AM, Re A, Russo D, Rossi G.

Leuk Lymphoma. 2019 May 23:1-7. doi: 10.1080/10428194.2019.1613535. [Epub ahead of print]

PMID:
31120311
5.

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.

Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, D'Adda M, Farina M, Bucelli C, Scaffidi L, Toffoletti E, Deambrogi C, Stagno F, Bergamaschi M, Franceschini L, Abruzzese E, Divona MD, Gobbi M, Di Raimondo F, Gaidano G, Tiribelli M, Bonifacio M, Cattaneo C, Iurlo A, Russo D.

Cancer Med. 2019 May;8(5):2041-2055. doi: 10.1002/cam4.2087. Epub 2019 Apr 4.

6.

Zebrafish disease models in hematology: Highlights on biological and translational impact.

Zizioli D, Mione M, Varinelli M, Malagola M, Bernardi S, Alghisi E, Borsani G, Finazzi D, Monti E, Presta M, Russo D.

Biochim Biophys Acta Mol Basis Dis. 2019 Mar 1;1865(3):620-633. doi: 10.1016/j.bbadis.2018.12.015. Epub 2018 Dec 26. Review.

PMID:
30593895
7.

Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing.

Piccaluga PP, Rapezzi D, Gazzola A, Malagola M, Visani G, Gallamini A.

Bone Marrow Transplant. 2019 Jan;54(1):159-163. doi: 10.1038/s41409-018-0268-4. Epub 2018 Aug 16. No abstract available.

PMID:
30116015
8.

Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria.

Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, Delia M, Ballanti S, Marchesi F, Mancini V, Orciuolo E, Cesaro S, Prezioso L, Fanci R, Nadali G, Chierichini A, Facchini L, Picardi M, Malagola M, Orlando V, Trecarichi EM, Tumbarello M, Aversa F, Rossi G, Pagano L; SEIFEM Group.

Ann Hematol. 2018 Sep;97(9):1717-1726. doi: 10.1007/s00277-018-3341-6. Epub 2018 Apr 28.

PMID:
29705860
9.

The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era.

Morello E, Malagola M, Bernardi S, Pristipino C, Russo D.

Blood Res. 2018 Mar;53(1):3-6. doi: 10.5045/br.2018.53.1.3. Epub 2018 Mar 27. No abstract available.

10.

Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years.

Polverelli N, Malagola M, Turra A, Skert C, Perucca S, Chiarini M, Cattina F, Rambaldi B, Cancelli V, Morello E, Schieppati F, Bernardi S, Zanaglio C, Sottini A, Giustini V, Imberti L, Montanelli A, Russo D.

Leuk Lymphoma. 2018 Nov;59(11):2700-2705. doi: 10.1080/10428194.2018.1439584. Epub 2018 Mar 12. No abstract available.

PMID:
29527964
11.

Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor.

Cattina F, Bernardi S, Mantovani V, Toffoletti E, Santoro A, Pastore D, Martino B, Console G, Martinelli G, Malagola M.

Hematol Rep. 2017 Sep 26;9(3):7051. eCollection 2017 Sep 26. No abstract available.

12.

Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation.

Almici C, Skert C, Bruno B, Bianchetti A, Verardi R, Di Palma A, Neva A, Braga S, Piccinelli G, Piovani G, Malagola M, Bernardi S, Giaccone L, Brunello L, Festuccia M, Baeten K, Russo D, Marini M.

Bone Marrow Transplant. 2017 Dec;52(12):1637-1642. doi: 10.1038/bmt.2017.194. Epub 2017 Sep 11.

PMID:
28892085
13.

Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.

Moschetta M, Kawano Y, Sacco A, Belotti A, Ribolla R, Chiarini M, Giustini V, Bertoli D, Sottini A, Valotti M, Ghidini C, Serana F, Malagola M, Imberti L, Russo D, Montanelli A, Rossi G, Reagan MR, Maiso P, Paiva B, Ghobrial IM, Roccaro AM.

Curr Osteoporos Rep. 2017 Oct;15(5):499-506. doi: 10.1007/s11914-017-0399-3. Review.

PMID:
28889371
14.

Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence?

Malagola M, Rambaldi B, Ravizzola G, Polverelli N, Turra A, Morello E, Skert C, Cancelli V, Cattina F, Bernardi S, Perucca S, Signorini L, Stellini R, Castelli F, Caruso A, Russo D.

Infect Control Hosp Epidemiol. 2017 Sep;38(9):1131-1132. doi: 10.1017/ice.2017.157. Epub 2017 Jul 31. No abstract available.

PMID:
28758618
15.

Bacterial Blood Stream Infections Negatively Impact on Outcome of Patients Treated with Allogeneic Stem Cell Transplantation: 6 Years Single-Centre Experience.

Malagola M, Rambaldi B, Ravizzola G, Cattaneo C, Borlenghi E, Polverelli N, Turra A, Morello E, Skert C, Cancelli V, Cattina F, Giannetta G, Bernardi S, Perucca S, Almici C, Roccaro A, Signorini L, Stellini R, Castelli F, Caruso A, Russo D.

Mediterr J Hematol Infect Dis. 2017 Jun 20;9(1):e2017036. doi: 10.4084/MJHID.2017.036. eCollection 2017.

16.

The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.

Sacco A, Fenotti A, Affò L, Bazzana S, Russo D, Presta M, Malagola M, Anastasia A, Motta M, Patterson CJ, Rossi G, Imberti L, Treon SP, Ghobrial IM, Roccaro AM.

Oncotarget. 2017 May 23;8(21):35435-35444. doi: 10.18632/oncotarget.16130. Review.

17.

Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation.

Skert C, Perucca S, Chiarini M, Giustini V, Sottini A, Ghidini C, Martellos S, Cattina F, Rambaldi B, Cancelli V, Malagola M, Turra A, Polverelli N, Bernardi S, Imberti L, Russo D.

PLoS One. 2017 Apr 11;12(4):e0175337. doi: 10.1371/journal.pone.0175337. eCollection 2017.

18.

Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells).

Perucca S, Di Palma A, Piccaluga PP, Gemelli C, Zoratti E, Bassi G, Giacopuzzi E, Lojacono A, Borsani G, Tagliafico E, Scupoli MT, Bernardi S, Zanaglio C, Cattina F, Cancelli V, Malagola M, Krampera M, Marini M, Almici C, Ferrari S, Russo D.

PLoS One. 2017 Feb 23;12(2):e0172430. doi: 10.1371/journal.pone.0172430. eCollection 2017.

19.

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.

Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, Kanakry CG, Gruhn B, Buccisano F, Devine B, Walter RB.

Haematologica. 2017 May;102(5):865-873. doi: 10.3324/haematol.2016.159343. Epub 2017 Jan 25. Review.

20.

Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo.

Malagola M, Cancelli V, Skert C, Leali PF, Ferrari E, Tiburzi A, Sala ML, Donnini I, Chiusolo P, Mussetti A, Battista M, Turra A, Cattina F, Rambaldi B, Schieppati F, Polverelli N, Bernardi S, Perucca S, Marini M, Laszlo D, Savignano C, Patriarca F, Corradini P, Piccirillo N, Sica S, Bosi A, Russo D.

Transplantation. 2016 Dec;100(12):e147-e155.

PMID:
27861297
21.

Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.

Malagola M, Papayannidis C, Baccarani M.

Ann Hematol. 2016 Apr;95(5):681-93. doi: 10.1007/s00277-016-2617-y. Epub 2016 Feb 19. Review.

PMID:
26891878
22.

Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.

Malagola M, Skert C, Borlenghi E, Chiarini M, Cattaneo C, Morello E, Cancelli V, Cattina F, Cerqui E, Pagani C, Passi A, Ribolla R, Bernardi S, Giustini V, Lamorgese C, Ruggeri G, Imberti L, Caimi L, Russo D, Rossi G.

Cancer Med. 2016 Feb;5(2):265-74. doi: 10.1002/cam4.593. Epub 2015 Dec 29.

23.

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment.

Russo D, Malagola M, Skert C, Cancelli V, Turri D, Pregno P, Bergamaschi M, Fogli M, Testoni N, De Vivo A, Castagnetti F, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Cambrin GR, Nicolini G, Abruzzese E, Tiribelli M, Bigazzi C, Usala E, Russo S, Russo-Rossi A, Lunghi M, Bocchia M, D'Emilio A, Santini V, Girasoli M, Lorenzo RD, Bernardi S, Palma AD, Cesana BM, Soverini S, Martinelli G, Rosti G, Baccarani M.

Blood Cancer J. 2015 Sep 18;5:e347. doi: 10.1038/bcj.2015.75.

24.

An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes.

Cocco L, Finelli C, Mongiorgi S, Clissa C, Russo D, Bosi C, Quaranta M, Malagola M, Parisi S, Stanzani M, Ramazzotti G, Mariani GA, Billi AM, Manzoli L, Follo MY.

J Leukoc Biol. 2015 Nov;98(5):769-80. doi: 10.1189/jlb.2MA1114-541R. Epub 2015 May 14.

PMID:
25977289
25.

Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

Carlo-Stella C, Ricci F, Dalto S, Mazza R, Malagola M, Patriarca F, Viviani S, Russo D, Giordano L, Castagna L, Corradini P, Santoro A.

Oncologist. 2015 Mar;20(3):323-8. doi: 10.1634/theoncologist.2014-0420. Epub 2015 Feb 10.

26.

Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation.

Malagola M, Skert C, Ruggeri G, Turra A, Ribolla R, Cancelli V, Cattina F, Alghisi E, Bernardi S, Perucca S, Di Palma A, Borlenghi E, Pagani C, Rossi G, Caimi L, Russo D.

Biomed Res Int. 2014;2014:123079. doi: 10.1155/2014/123079. Epub 2014 Aug 17.

27.

Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease.

Almici C, Skert C, Verardi R, Di Palma A, Bianchetti A, Neva A, Braga S, Malagola M, Turra A, Marini M, Russo D.

Transplantation. 2014 Oct 15;98(7):706-12. doi: 10.1097/TP.0000000000000385.

PMID:
25119132
28.

A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation.

Skert C, Fogli M, Garaffa E, Perucca S, Fiorentini S, Cancelli V, Turra A, Ribolla R, Filì C, Malagola M, Bergonzi C, Cattina F, Bernardi S, Caruso A, Di Palma A, Russo D.

Transpl Infect Dis. 2014 Oct;16(5):697-712. doi: 10.1111/tid.12264. Epub 2014 Jul 12.

PMID:
25040166
29.

Conditioning regimens in acute myeloid leukemia.

Visani G, Malagola M, Guiducci B, Lucesole M, Loscocco F, Gabucci E, Paolini S, Piccaluga PP, Isidori A.

Expert Rev Hematol. 2014 Aug;7(4):465-79. doi: 10.1586/17474086.2014.939066. Review.

PMID:
25025371
30.

Central nervous system angiitis in Hodgkin's disease.

Morotti A, Malagola M, Cancelli V, Gatti E, Codella M, Rao R, Pezzini A, Gasparotti R, Russo D, Padovani A.

J Neurol. 2013 Nov;260(11):2897-9. doi: 10.1007/s00415-013-7122-9. Epub 2013 Oct 18. No abstract available.

PMID:
24136583
31.

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.

Malagola M, Breccia M, Skert C, Cancelli V, Soverini S, Iacobucci I, Cattina F, Liberati AM, Tiribelli M, Annunziata M, Trabacchi E, De Vivo A, Castagnetti F, Martinelli G, Fogli M, Stagno F, Pica G, Iurlo A, Pregno P, Abruzzese E, Pardini S, Bocchia M, Russo S, Pierri I, Lunghi M, Barulli S, Merante S, Mandelli F, Alimena G, Rosti G, Baccarani M, Russo D.

Am J Hematol. 2014 Feb;89(2):119-24. doi: 10.1002/ajh.23593.

32.

Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease.

Malerba M, Clini E, Malagola M, Avanzi GC.

Expert Rev Hematol. 2013 Aug;6(4):475-83. doi: 10.1586/17474086.2013.814835. Review.

PMID:
23991933
33.

Treatment of chronic myeloid leukemia elderly patients in the tyrosine kinase inhibitor era.

Russo D, Malagola M, Skert C, Filì C, Bergonzi C, Cancelli V, Cattina F.

Curr Cancer Drug Targets. 2013 Sep;13(7):755-67. Review.

PMID:
23941515
34.

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.

Russo D, Martinelli G, Malagola M, Skert C, Soverini S, Iacobucci I, De Vivo A, Testoni N, Castagnetti F, Gugliotta G, Turri D, Bergamaschi M, Pregno P, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Fava C, Abruzzese E, Tiribelli M, Bigazzi C, Cesana BM, Rosti G, Baccarani M.

Blood. 2013 Jun 27;121(26):5138-44. doi: 10.1182/blood-2013-01-480194. Epub 2013 May 15. Erratum in: Blood. 2014 May 1;123(18):2902. Bergamaschi, Michela [corrected to Bergamaschi, Micaela].

35.

Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the Notch pathway.

Alghisi E, Distel M, Malagola M, Anelli V, Santoriello C, Herwig L, Krudewig A, Henkel CV, Russo D, Mione MC.

Leukemia. 2013 Nov;27(11):2229-41. doi: 10.1038/leu.2013.132. Epub 2013 Apr 29.

PMID:
23625115
36.

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.

Filì C, Malagola M, Follo MY, Finelli C, Iacobucci I, Martinelli G, Cattina F, Clissa C, Candoni A, Fanin R, Gobbi M, Bocchia M, Defina M, Spedini P, Skert C, Manzoli L, Cocco L, Russo D.

Clin Cancer Res. 2013 Jun 15;19(12):3297-308. doi: 10.1158/1078-0432.CCR-12-3540. Epub 2013 Apr 17.

37.

Profile of toll-like receptors on peripheral blood cells in relation to acute graft-versus-host disease after allogeneic stem cell transplantation.

Skert C, Fogli M, Perucca S, Garrafa E, Fiorentini S, Filì C, Bergonzi C, Malagola M, Turra A, Colombi C, Cattina F, Alghisi E, Caruso A, Russo D.

Biol Blood Marrow Transplant. 2013 Feb;19(2):227-34. doi: 10.1016/j.bbmt.2012.09.013. Epub 2012 Sep 26.

38.

Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.

Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S, Ottaviani E, Ferrari A, Michelutti A, Simeone E, Astolfi A, Abbenante MC, Parisi S, Cattina F, Malagola M, Russo D, Damiani D, Gherlinzoni F, Gottardi M, Baccarani M, Fanin R, Martinelli G.

Pharmacogenomics J. 2013 Aug;13(4):335-41. doi: 10.1038/tpj.2012.13. Epub 2012 May 15.

PMID:
22584460
39.

A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients.

Malagola M, Skert C, Vignetti M, Piciocchi A, Martinelli G, Alimena G, Mecucci C, Testoni N, Iacobucci I, Clavio M, Gobbi M, Candoni A, Damiani D, Bocchia M, Lauria F, Zaccaria A, Mazza P, Visani G, Peli A, Colombi C, Cancelli V, Mancini M, Foà R, Martelli M, Cantore N, Di Raimondo F, Petrini M, De Fabritiis P, Fioritoni G, Nobile F, Fabbiano F, Specchia G, Baccarani M, Lo Coco F, Amadori S, Mandelli F, Russo D.

Leuk Lymphoma. 2011 Dec;52(12):2329-35. doi: 10.3109/10428194.2011.596965. Epub 2011 Jul 12.

PMID:
21745171
40.

Myeloid Sarcoma: The Clinician's Point of View.

Malagola M, Tiribelli M, Russo D, Candoni A, Visani G, Isidori A.

Leuk Res Treatment. 2011;2011:410291. doi: 10.4061/2011/410291. Epub 2011 Apr 27.

41.

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.

Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, Falda M, Guidi S, Ciceri F, Bonini A, Ferrari S, Malagola M, Morello E, Milone G, Bruno B, Mordini N, Viviani S, Levis A, Giordano L, Santoro A, Corradini P; Gruppo Italiano Trapianto di Midollo Osseo.

Blood. 2010 May 6;115(18):3671-7. doi: 10.1182/blood-2009-12-253856. Epub 2010 Mar 10.

42.

Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.

Damiani D, Tiribelli M, Michelutti A, Geromin A, Cavallin M, Fabbro D, Pianta A, Malagola M, Damante G, Russo D, Fanin R.

Leuk Res. 2010 Jul;34(7):942-5. doi: 10.1016/j.leukres.2010.01.008. Epub 2010 Jan 31.

PMID:
20122734
43.

FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.

Candoni A, Simeone E, Tiribelli M, Malagola M, Russo D, Fanin R.

Am J Hematol. 2009 Oct;84(10):690-2. doi: 10.1002/ajh.21516. No abstract available.

44.

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

Roccaro AM, Ghobrial IM, Blotta S, Treon SP, Malagola M, Anderson KC, Richardson PG, Russo D.

Biologics. 2008 Sep;2(3):419-31.

45.

Leukemia and multi-drug resistance: too many mechanisms of drug resistance or too many doctors resistant?

Malagola M, Baccarani M, Russo D.

Leuk Lymphoma. 2009 Jun;50(6):1058-60. doi: 10.1080/10428190902898255. No abstract available.

PMID:
19504396
46.

Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.

Visani G, Piccaluga P, Malagola M, Isidori A.

Leukemia. 2009 Sep;23(9):1687-8. doi: 10.1038/leu.2009.96. Epub 2009 May 7. No abstract available.

PMID:
19421228
47.

Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study.

Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Filì C, Lucchi P, Malagola M, Bergonzi C, Roccaro A, Peli A, Ricotta D, Caimi L, Fanin R, Baccarani M, Russo D.

Bone Marrow Transplant. 2009 Dec;44(11):729-37. doi: 10.1038/bmt.2009.80. Epub 2009 Apr 27.

PMID:
19398965
48.

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.

Malagola M, Peli A, Damiani D, Candoni A, Tiribelli M, Martinelli G, Piccaluga PP, Paolini S, De Rosa F, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Filì C, Fanin R, Baccarani M, Russo D.

Eur J Haematol. 2008 Nov;81(5):354-63. doi: 10.1111/j.1600-0609.2008.01122.x. Epub 2008 Aug 19.

PMID:
18637030
49.

Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.

Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, Piccaluga PP, Michelutti A, Simeone E, Damiani D, Russo D, Fanin R.

Leuk Res. 2008 Dec;32(12):1800-8. doi: 10.1016/j.leukres.2008.05.011. Epub 2008 Jul 14.

PMID:
18621416
50.

Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients.

Piccaluga PP, Martinelli G, Isidori A, Malagola M, Rondoni M, Paolini S, Amabile M, Iacobucci I, Baccarani M, Visani G.

Leukemia. 2008 Aug;22(8):1617-8. doi: 10.1038/leu.2008.10. Epub 2008 Feb 14. No abstract available.

PMID:
18273047

Supplemental Content

Loading ...
Support Center